Sunshine Biopharma Inc (SBFM)

[TenKay]

The offering fails if it cannot move stock into the market. This is an offering to move onto Nasdaq. Nasdaq does not price based on hype but real numbers. So there are two factors at play, how much of a discount to move the stock and what Nasdaq will value the company at…(and it WILL be less than the OTC).

Aegis as the underwriter will have to sell the stock to their clients (brokers) at a discount to entice them to buy and in turn the brokers will sell to their clients which will also require a discount.

That is how this works and pretty much all OTC stock that uplist via an offering end up in the 50-70% range of discounts. There might be some examples out there of less…and certainly at least 20%.

But make no mistake…whatever this stock is trading at the day before the S-1 goes effective and the offering closes, it will be trading a lot lower out of the gate on nasdaq.

I have seen this play out many times.

Folks can’t say they weren’t warned.